WO2019094543A3 - Selectively killing chemotherapy- and radiation therapy-resistant cancer cells using cell membrane-pore forming peptides - Google Patents

Selectively killing chemotherapy- and radiation therapy-resistant cancer cells using cell membrane-pore forming peptides

Info

Publication number
WO2019094543A3
WO2019094543A3 PCT/US2018/059747 US2018059747W WO2019094543A3 WO 2019094543 A3 WO2019094543 A3 WO 2019094543A3 US 2018059747 W US2018059747 W US 2018059747W WO 2019094543 A3 WO2019094543 A3 WO 2019094543A3
Authority
WO
WIPO (PCT)
Prior art keywords
pore forming
cell membrane
cancer
cancer cell
acid sequence
Prior art date
Application number
PCT/US2018/059747
Other languages
French (fr)
Other versions
WO2019094543A2 (en
Inventor
Joseph RUBENFELD
Original Assignee
Rubenfeld Joseph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubenfeld Joseph filed Critical Rubenfeld Joseph
Publication of WO2019094543A2 publication Critical patent/WO2019094543A2/en
Publication of WO2019094543A3 publication Critical patent/WO2019094543A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention concerns methods of killing a cancer treatment resistant cancer cell in a mammal, including a human using a therapeutic dose of a pharmaceutical formulation comprising a cell membrane-pore forming peptides including PNC-27 and PNC-28. The method of using the cell membrane-pore forming peptides of the present invention is localized to the exterior surface of the cancer cell. The cancer cell membrane pore forming peptide comprises a first amino acid sequence attached at its carboxyl terminal end to an amino terminal end of a second amino acid sequence, wherein the first amino acid sequence can bind to an HDM-2 protein, and wherein the second amino acid sequence can function as a membrane resident peptide. Because the method of using the cell membrane-pore forming peptides of the present invention for the killing cancer treatment resistant cancer cell does not depend upon the obtaining of an intracellular concentration of the cancer cell membrane pore forming peptide in the cancer cell, the invention method is surprisingly unaffected by cancer treatment resistance mechanisms which render existing cancer treatment methods incompletely effective in eradicating cancer in the mammal or in the human subject.
PCT/US2018/059747 2017-11-10 2018-11-08 Killing chemotherapy-resistant cancer cells and radiation therapy resistant cancer cells using cell membrane-pore forming peptides which do not kill normal cells WO2019094543A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201715809108A 2017-11-10 2017-11-10
US15/809,108 2017-11-10

Publications (2)

Publication Number Publication Date
WO2019094543A2 WO2019094543A2 (en) 2019-05-16
WO2019094543A3 true WO2019094543A3 (en) 2020-04-09

Family

ID=66439000

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/059747 WO2019094543A2 (en) 2017-11-10 2018-11-08 Killing chemotherapy-resistant cancer cells and radiation therapy resistant cancer cells using cell membrane-pore forming peptides which do not kill normal cells

Country Status (1)

Country Link
WO (1) WO2019094543A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170209521A1 (en) * 2007-11-26 2017-07-27 The Research Foundation For The State University Of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170209521A1 (en) * 2007-11-26 2017-07-27 The Research Foundation For The State University Of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAVITT, K ET AL.: "The Anti-Cancer Peptide, PNC-27, Induces Tumor Cell Necrosis of a Poorly Differentiated Non-Solid Tissue Human Leukemia Cell Line that Depends on Expression of HDM-2 in the Plasma Membrane of these Cells", ANNALS OF CLINICAL AND LABORATORY SCIENCE, vol. 44, no. 3, 2014, pages 241 - 248, XP055700920 *
JAGOT-LACOUSSIERE, L ET AL.: "A Cell-Penetrating Peptide Targeting AAC-11 Specifically Induces Cancer Cells Death", CANCER RESEARCH, vol. 76, no. 18, 12 July 2016 (2016-07-12), pages 5479 - 5490 *
SARAFRAZ-YAZDI, E ET AL.: "Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA., vol. 107, no. 5, 11 January 2010 (2010-01-11), pages 1918 - 1923, XP055519445, DOI: 10.1073/pnas.0909364107 *

Also Published As

Publication number Publication date
WO2019094543A2 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
Ali et al. Venom proteomic characterization and relative antivenom neutralization of two medically important Pakistani elapid snakes (Bungarus sindanus and Naja naja)
EA202190669A1 (en) PROCESS FOR OBTAINING VACCINE COMPOSITION
WO2015188132A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
CY1119498T1 (en) Leptin-ABD Fusion Polypeptides with Enhanced Duration of Action
WO2015024667A8 (en) Method for increasing expression of rna-encoded proteins
WO2017081211A3 (en) Antigen-binding polypeptides directed against cd38
WO2014172376A3 (en) Markers of tumor cell response to anti-cancer therapy
BR112017005736A2 (en) peptidomimetic macrocycles and formulations thereof
EP3889185A3 (en) Composition for improving the solubility of a protein or peptide by using immunoglobulin fc fragment linkage
WO2007011606A3 (en) USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
PH12014501363A1 (en) Anticancer fusion protein
IL172783A0 (en) Rasgap derived peptide for selectively killing cancer cells
WO2016201450A3 (en) Cancer treatment and diagnosis
PE20190733A1 (en) ANTIBODIES AGAINST DENGUE VIRUS, POLYPEPTIDES CONTAINING VARIANTS FC REGIONS, AND METHODS OF USE
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
JP2017529870A5 (en)
Ikonomova et al. Engineering improved variants of the antifungal peptide histatin 5 with reduced susceptibility to Candida albicans secreted aspartic proteases and enhanced antimicrobial potency
EP4406613A3 (en) Immunogenic arginase peptides
WO2020103961A3 (en) Brain tumor-targeting peptide and application thereof
MX2019002664A (en) Antigen binding protein against her3.
EP4361634A3 (en) Methods for treating and monitoring the status of cancer
WO2012143477A3 (en) Anticancer fusion protein
KR20150050646A (en) Fusion peptide and use thereof for cell membrane penetrating
WO2015043566A8 (en) Cyclic amyloid-beta-binding peptides and the use thereof
WO2019094543A3 (en) Selectively killing chemotherapy- and radiation therapy-resistant cancer cells using cell membrane-pore forming peptides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18876773

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18876773

Country of ref document: EP

Kind code of ref document: A2